Back to results
US 2024/0190987 A1Published application
Engineered EpCam Binding Antibodies
AssigneeTigaTX, Inc.
InventorsZachary B. HILL, Alexander J. MARTINKO, Allison COOKE, Hai TRAN, Erin SIMONDS, Sunandan BANERJEE
Life of this patent
Estimating the term…
Abstract
The present invention uses an indinavir based mechanism of “chemically induced dimerization” to enable a precise temporal control of the activity of a T cell engaging complex in a patient.
Claims24
(canceled)
An EpCAM binding antibody or fragment thereof that comprises:
- (a) a variable heavy chain (vh) that comprises:
- (i) a vh complementary determining region 1 (vhCDR1) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2545, SEQ ID NO:
- 2745, SEQ ID NO:
- 2801, SEQ ID NO:
- 2809, SEQ ID NO:
- 2817, SEQ ID NO:
- 2825, SEQ ID NO:
- 2833, SEQ ID NO:
- 2841, SEQ ID NO:
- 2865, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (ii) a vh complementary determining region 2 (vhCDR2) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2746, SEQ ID NO:
- 2810, SEQ ID NO:
- 2554, SEQ ID NO:
- 2546, SEQ ID NO:
- 2898, SEQ ID NO:
- 2890, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (iii) a vh complementary determining region 3 (vhCDR3) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2547, SEQ ID NO:
- 2747, SEQ ID NO:
- 2851, SEQ ID NO:
- 2859, SEQ ID NO:
- 2907, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- and
- (b) a variable light chain (vl) that comprises:
- (i) a vl complementary determining region 1 (vlCDR1) having an amino acid sequence that comprises SEQ ID NO:
- 2548, SEQ ID NO:
- 2748 or either of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (ii) a vl complementary determining region 2 (vlCDR2) having an amino acid sequence that comprises SEQ ID NO:
- 2549, SEQ ID NO:
- 2749 or either of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- and
- (iii) a vl complementary determining region 3 (vlCDR3) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2550, SEQ ID NO:
- 2750, SEQ ID NO:
- 2918, SEQ ID NO:
- 2926, SEQ ID NO:
- 2934, SEQ ID NO:
- 2942, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM.
41 more elements
An EpCAM binding domain or fragment thereof that comprises:
- (a) a variable heavy chain (vh) that comprises:
- (i) a vh complementary determining region 1 (vhCDR1) having an amino acid sequence that comprises SEQ ID NO:
- 2761 or SEQ ID NO:
- 2761 having 1 to 3 mutations and that is capable of binding EpCAM;
- (ii) a vh complementary determining region 2 (vhCDR2) having an amino acid sequence that comprises SEQ ID NO:
- 2762 and that is capable of binding EpCAM;
- (iii) a vh complementary determining region 3 (vhCDR3) having an amino acid sequence that comprises SEQ ID NO:
- 2763 or SEQ ID NO:
- 2763 having 1 to 3 mutations and that is capable of binding EpCAM;
- (b) a variable light chain (vl) that comprises:
- (i) a vl complementary determining region 1 (vlCDR1) having an amino acid sequence that comprises SEQ ID NO:
- 2764 or SEQ ID NO:
- 2764 having 1 to 3 mutations and that is capable of binding EpCAM,
- (ii) a vl complementary determining region 2 (vlCDR2) having an amino acid sequence that comprises SEQ ID NO:
- 2765 or SEQ ID NO:
- 2765 having 1 to 3 mutations and that is capable of binding EpCAM, and
- (iii) a vl complementary determining region 3 (vlCDR3) having an amino acid sequence that comprises SEQ ID NO:
- 2766 or SEQ ID NO:
- 2766 having 1 to 3 mutations and that is capable of binding EpCAM.
16 more elements
A method of treating cancer in a subject, the method comprising administering to the subject an EpCAM binding antibody or fragment thereof that comprises:
- (a) a variable heavy chain (vh) that comprises:
- (i) a vh complementary determining region 1 (vhCDR1) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2545, SEQ ID NO:
- 2745, SEQ ID NO:
- 2801, SEQ ID NO:
- 2809, SEQ ID NO:
- 2817, SEQ ID NO:
- 2825, SEQ ID NO:
- 2833, SEQ ID NO:
- 2841, SEQ ID NO:
- 2865, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (ii) a vh complementary determining region 2 (vhCDR2) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2746, SEQ ID NO:
- 2810, SEQ ID NO:
- 2554, SEQ ID NO:
- 2546, SEQ ID NO:
- 2898, SEQ ID NO:
- 2890, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (iii) a vh complementary determining region 3 (vhCDR3) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2547, SEQ ID NO:
- 2747, SEQ ID NO:
- 2851, SEQ ID NO:
- 2859, SEQ ID NO:
- 2907, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- and
- (b) a variable light chain (vl) that comprises:
- (i) a vl complementary determining region 1 (vlCDR1) having an amino acid sequence that comprises SEQ ID NO:
- 2548, SEQ ID NO:
- 2748 or either of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- (ii) a vl complementary determining region 2 (vlCDR2) having an amino acid sequence that comprises SEQ ID NO:
- 2549, SEQ ID NO:
- 2749 or either of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM;
- and
- (iii) a vl complementary determining region 3 (vlCDR3) having an amino acid sequence that comprises:
- SEQ ID NO:
- 2550, SEQ ID NO:
- 2750, SEQ ID NO:
- 2918, SEQ ID NO:
- 2926, SEQ ID NO:
- 2934, SEQ ID NO:
- 2942, or any of these amino acid sequences having 1 to 3 mutations and that is capable of binding EpCAM.
41 more elements
Dependencies are inferred from the claim text.